Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials

• Status: Terminated
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will explore how allergy symptoms experienced during the grass pollen season compare to symptoms experienced in the Environmental Exposure Chamber (EEC).

There are 2 treatments in this study. Both treatments are injected under the skin. Allergovit® Grasses works by helping the body's immune system get used to grass-pollen before the grass pollen season begins which may lead to decreased sensitivity and reduced allergy symptoms during the grass season. Placebo treatment does not contain grass pollen mixture, and is not expected to reduce allergic symptoms overtime.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Allergopharma GmbH & Co. KG
• Collaborator: Inflamax Research Incorporated

Criteria

Inclusion Criteria:

• IgE-mediated seasonal allergic rhinitis/rhinoconjunctivitis with or without allergic asthma

• positive skin prick test

• specific IgE ≥ 0.70 kU/L to mixture of grass pollen allergens

• symptom score of at least 4 per day during the week following the peak-pollen count in the baseline season

Exclusion Criteria:

• undergone previous specific immunotherapy with grass pollen allergens in any formulation less than 5 years prior to the screening date

• currently undergoing any sort of immunotherapy, or has ever undergone specific immunotherapy with unknown allergen

• allergens which are expected to interfere with the grass pollen season

• uncontrolled or partly controlled asthma

• patients with contraindications for SIT